Nature, 24 July 2020
Riva, L., Yuan, S., Yin, X. et al.
- Profiled a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules.
- Thirteen were found to harbor effective concentrations likely commensurate with achievable therapeutic doses in patients, including the PIKfyve kinase inhibitor apilimod, and the cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334.
- Since most of the molecules identified in this study have already advanced into the clinic, the known pharmacological and human safety profiles of these compounds will enable accelerated preclinical and clinical evaluation of these drugs for the treatment of COVID-19.